Celecoxib + Placebo

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Adenomatous Polyposis Coli

Conditions

Adenomatous Polyposis Coli

Trial Timeline

Sep 1, 2006 → Oct 1, 2013

NCT ID

NCT00585312

About Celecoxib + Placebo

Celecoxib + Placebo is a phase 3 stage product being developed by Pfizer for Adenomatous Polyposis Coli. The current trial status is terminated. This product is registered under clinical trial identifier NCT00585312. Target conditions include Adenomatous Polyposis Coli.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01186887	Pre-clinical	Completed	Feb 1, 2009	Apr 1, 2013	Pain
NCT00583453	Phase 2	Completed	Oct 1, 2007	May 1, 2016	Tonsillitis
NCT00359151	Approved	Terminated	Nov 1, 2006	Jul 1, 2007	Osteoarthritis
NCT00585312	Phase 3	Terminated	Sep 1, 2006	Oct 1, 2013	Adenomatous Polyposis Coli
NCT00300729	Phase 3	UNKNOWN	May 1, 2006	Sep 1, 2010	Non-Small Cell Lung Cancer
NCT00640627	Approved	Completed	Dec 1, 2003	Sep 1, 2004	Osteoarthritis, Knee
NCT00698204	Phase 2	Completed	Jul 1, 2003	Dec 1, 2013	Oral Mucositis
NCT00639483	Phase 2	Completed	Mar 1, 2003	Jan 1, 2004	Schizophrenia
NCT00471341	Approved	Completed	Jul 1, 2002	Dec 1, 2004	Hypertension and Coronary Artery Disease
NCT00582660	Phase 2	Completed	Dec 1, 2001	Jun 1, 2008	Colorectal Adenoma
NCT02840162	Phase 2	Terminated	May 1, 2001	May 1, 2011	Adenocarcinoma of the Prostate

Competing Products

3 competing products in Adenomatous Polyposis Coli

See all competitors

Product	Company	Stage	Hype Score
MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks	Merck	Approved	85
Celecoxib	Pfizer	Pre-clinical	22
REC-4881 + Placebo	Recursion Pharmaceuticals	Phase 1/2	36

Other Products from Pfizer